Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.55 |
| ▸ | F10 | P00742 | 11/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 10/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 10/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 10/20 | 0.44 |
| ▸ | PLG | P00747 | 8/20 | 0.44 |
| ▸ | F2 | P00734 | 8/20 | 0.44 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4682332 | 0.87 | ESR1 (0.50) | ESR1ESR2F10PRSS1PRSS2 | |
| SCHEMBL30950127 | 0.84 | ESR1 (0.56) | ESR1ESR2F10PRSS1PRSS2 | |
| SCHEMBL21834083 | 0.84 | ESR1 (0.56) | ESR1ESR2F10PRSS1PRSS2 | |
| SCHEMBL31670428 | 0.83 | ESR1 (0.55) | ESR1ESR2F10PRSS1PRSS2 | |
| SCHEMBL12862882 | 0.81 | ESR1 (0.67) | ESR1ESR2ABHD6PKMMEN1 | |
| SCHEMBL19641653 | 0.80 | ESR2 (0.57) | ESR1ESR2F10PRSS1PRSS2 | |
| SCHEMBL3540135 | 0.77 | ESR1 (0.53) | ESR1ESR2F10ABHD6PKM | |
| SCHEMBL28620925 | 0.77 | ESR1 (0.55) | ESR1ESR2ABHD6PKMHRH3 | |
| SCHEMBL14677183 | 0.76 | ESR2 (0.59) | ESR1ESR2ABHD6PKMMEN1 | |
| SCHEMBL21834082 | 0.76 | ESR1 (0.57) | ESR1ESR2F10ABHD6PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1430040-A1 | BENZOTHIAZEPINE DERIVATIVES | Astrazeneca AB (SE) | 2004-06-23 | — | — | EP | claimed |
| WO-2003020710-A1 | BENZOTHIAZEPINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-03-13 | — | — | WO | claimed |
| EP-1392306-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | AVENTIS PHARMA LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-7211586-B2 | Substituted tetrahydroisoquinolines | AVENTIS PHARMA LIMITED (GB) | 2007-05-01 | — | — | US | disclosed |
| US-20040122047-A1 | Substituted tetrahydroisoquinolines | AVENTIS PHARMA LIMITED (GB) | 2004-06-24 | — | — | US | disclosed |
| EP-1392306-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | Aventis Pharma Limited (GB) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002098426-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | AVENTIS PHARMA LIMTIED (GB) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122047-A1 | Substituted tetrahydroisoquinolines | VCAM1, ITGA1, ITGB3 | ESR1 1482/4885ESR2 810/4885F10 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.